Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment in Aging

Authors not listed

Steven E Arnold, MD · 2020

Loss of proteostasis Human Randomized controlled trial

Abstract

In this research study we want to learn more about whether taking Niagen, a daily supplement containing a form of Vitamin B3, will improve cognitive function, mood, and daily activity in people with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-07-02 MST

Cite this

APA

Anonymous. (2020). A Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment in Aging. <em>Steven E Arnold, MD</em>. https://clinicaltrials.gov/study/NCT04078178

Vancouver

Anonymous. A Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment in Aging. Steven E Arnold, MD. 2020.

BibTeX

@misc{anon2020ACross, title = {A Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment in Aging}, author = {Anonymous}, journal = {Steven E Arnold, MD}, year = {2020}, }